Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Journal of Food and Pharmaceutical Science Journal of Food and Pharmaceutical Sciences
Almira, Deta
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Monoclonal Antibodies Aggregation during Administration to Patients and the Role of Pharmaceutical Excipients Almira, Deta; Nurcahya, Bekti Meilani; Rahmawati, Fita; Laksitorini, Marlyn Dian
Journal of Food and Pharmaceutical Sciences Vol 13, No 2 (2025): J.Food.Pharm.Sci
Publisher : Integrated Research and Testing Laboratory (LPPT) Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jfps.21391

Abstract

Monoclonal antibodies (mAbs) are powerful therapeutic agents known for their high specificity and effectiveness in treating complex diseases. Yet, one of their major challenges is their tendency to aggregate, which can reduce treatment efficacy and even trigger unwanted immune responses. This review focuses on how pharmaceutical excipients can help prevent antibody aggregation, particularly during the drug administration process, a phase often overlooked. We conducted a systematic literature search using Scopus, PubMed, and ScienceDirect, targeting studies on excipients and aggregation in therapeutic proteins. After applying the selection criteria, six original research articles were analyzed. The findings reveal that several excipients—such as L-arginine, polysorbates, trehalose derivatives, proline analogs, and cyclodextrins—can effectively stabilize mAbs. They work by reducing interfacial stress, minimizing protein–protein interactions, and preserving antibody structure during stress conditions like infusion or inhalation. These insights highlight the importance of choosing the right excipient based on the administration route to ensure antibody stability and therapeutic impact. By shifting the focus from formulation to administration, this review provides a practical perspective that can support the development of safer and more effective mAb therapies.
Monoclonal Antibodies Aggregation during Administration to Patients and the Role of Pharmaceutical Excipients Almira, Deta; Nurcahya, Bekti Meilani; Rahmawati, Fita; Laksitorini, Marlyn Dian
Journal of Food and Pharmaceutical Sciences Vol 13, No 2 (2025): J.Food.Pharm.Sci
Publisher : Integrated Research and Testing Laboratory (LPPT) Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jfps.21391

Abstract

Monoclonal antibodies (mAbs) are powerful therapeutic agents known for their high specificity and effectiveness in treating complex diseases. Yet, one of their major challenges is their tendency to aggregate, which can reduce treatment efficacy and even trigger unwanted immune responses. This review focuses on how pharmaceutical excipients can help prevent antibody aggregation, particularly during the drug administration process, a phase often overlooked. We conducted a systematic literature search using Scopus, PubMed, and ScienceDirect, targeting studies on excipients and aggregation in therapeutic proteins. After applying the selection criteria, six original research articles were analyzed. The findings reveal that several excipients—such as L-arginine, polysorbates, trehalose derivatives, proline analogs, and cyclodextrins—can effectively stabilize mAbs. They work by reducing interfacial stress, minimizing protein–protein interactions, and preserving antibody structure during stress conditions like infusion or inhalation. These insights highlight the importance of choosing the right excipient based on the administration route to ensure antibody stability and therapeutic impact. By shifting the focus from formulation to administration, this review provides a practical perspective that can support the development of safer and more effective mAb therapies.
Co-Authors Fita Rahmawati Marlyn Dian Laksitorini, Marlyn Dian Nurcahya, Bekti Meilani